SPY311.36-0.82 -0.26%
DIA263.33+0.16 0.06%
IXIC9,615.81-67.10 -0.69%
News
FBIO
--
0.00%
--
Mustang Bio to Host Virtual Annual Meeting of Stockholders
GlobeNewswire · 18h ago
The Daily Biotech Pulse: Positive Readout For Kezar, AstraZeneca Stitches Oncology Partnership, D-Day For Merck's Triple Combo Antibiotic
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peak (Biotech Stocks Hitting 52-week Highs June 3)
Benzinga · 19h ago
Fortress Biotech to Host Virtual Annual Meeting of Stockholders
GlobeNewswire · 2d ago
Avenue Therapeutics to Host Virtual Annual Meeting of Stockholders
GlobeNewswire · 6d ago
The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26)
Benzinga · 05/27 11:25
Fortress Biotech Announces Pricing of Series A Preferred Stock Offering
Fortress Biotech, Inc. (Common Stock: Nasdaq: FBIO) (Preferred Stock: Nasdaq: FBIOP) (“Fortress”), an innovative biopharmaceutical company, today announced that it has priced an underwritten public offering of 555,556 shares of its 9.375% Series A Cumulative R
GlobeNewswire · 05/27 01:30
Checkpoint Therapeutics to Host Virtual Annual Meeting of Stockholders
GlobeNewswire · 05/22 13:30
Fortress Biotech files for $75M mixed shelf
Fortress Biotech (NASDAQ:FBIO) has filed a prospectus for a $75M mixed shelf offering.
seekingalpha · 05/18 19:03
Fortress Biotech Files for up to $74M Mixed Shelf Offering
Benzinga · 05/18 10:09
Mustang Bio Announces Presentations at 23rd Annual Meeting of the American Society of Gene & Cell Therapy
GlobeNewswire · 05/12 13:00
Is Fortress Biotech, Inc.'s (NASDAQ:FBIO) CEO Pay Justified?
Simply Wall St. · 05/12 12:51
78 Biggest Movers From Yesterday
Gainers
Benzinga · 05/12 09:02
Fortress Biotech EPS beats by $0.05, beats on revenue
Fortress Biotech (NASDAQ:FBIO): Q1 Non-GAAP EPS of -$0.07; GAAP EPS of -$0.19 beats by $0.05. Revenue of $12.92M (+99.4% Y/Y) beats by $1.63M. Press Releas
seekingalpha · 05/12 01:52
Fortress Biotech Q1 Adj. EPS $(0.070), Same YoY
Fortress Biotech (NASDAQ:FBIO) reported quarterly losses of $(0.070) per share. This is unchanged from the same period last year.
Benzinga · 05/11 20:51
Avenue Therapeutics Reports First Quarter 2020 Financial Results and Recent Corporate Highlights
GlobeNewswire · 05/11 12:30
Earnings dominate premarket gainers
Seeking Alpha - Article · 05/08 13:15
Fortress Bio closes license deal with Columbia U. for cancer candidates
Seeking Alpha - Article · 05/08 11:44
Fortress Biotech Reports Exclusive Global License Deal With Columbia University To Develop Novel Oligonucleotide Platform To Treat Genetically-Driven Cancers
Fortress Biotech, Inc. (NASDAQ:FBIO) (“Fortress”), an innovative biopharmaceutical company, today announced that Oncogenuity, Inc. (“Oncogenuity”), a new Fortress partner company, has entered into
Benzinga · 05/08 11:34
Fortress Biotech Announces Exclusive Worldwide License Agreement With Columbia University to Develop Novel Oligonucleotide Platform for the Treatment of Genetically Driven Cancers
Oncogenuity, Inc., a Fortress partner company, enters into an agreement with Columbia University to develop a broad platform technology using oligonucleotides Initial target is.
GlobeNewswire · 05/08 11:30
Checkpoint Therapeutics Reports First Quarter 2020 Financial Results and Recent Corporate Highlights
NEW YORK, May 06, 2020 -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company focused on the acquisition,.
GlobeNewswire · 05/06 20:30